Fondaparinux (Arixtra)
General information
Class/mechanism: Selectively binds to antithrombin III (AT-III) and augments its activity to specifically inhibit activated Factor Xa. The risk of developing thrombus is reduced via inhibition of thrombin, which converts fibrinogen to fibrin in the coagulation cascade.[1]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Fondaparinux (Arixtra) package insert (locally hosted backup)[1]
- Fondaparinux (Arixtra) patient drug information (UpToDate)[2]
History of changes in FDA indication
- 12/07/2001: Initial FDA approval: prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in:
- patients undergoing hip fracture surgery;
- patients undergoing hip replacement surgery;
- patients undergoing knee replacement surgery.
History of changes in EMA indication
- 3/20/2002: Initial authorization
Also known as
- Brand names: Arixtra, Quixidar